Targets › MAGEA2
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2027.
Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. (UniProt, P43356)
Open in Phaseline: the race on MAGEA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| OSE Immunotherapeutics | OSE2101 peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an | TP53, ERBB2, CEA, MAGEA2, MAGEA3 | Phase 3 | Patients With Non-Small Cell Lung Cancer; Solid Advanced Tumor | Dec 2027 |
Patients With Non-Small Cell Lung Cancer (1) Solid Advanced Tumor (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.